Breaking Finance News

A report released today by Citigroup Inc. about Becton Dickinson and Co (NYSE:BDX) lowers the target price to $165.00

Citigroup Inc. lowered the stock price target of Becton Dickinson and Co (NYSE:BDX) to $165.00 stating a potential downside of -0.09%.

Previously on Friday August 05, 2016, UBS Securities reported on Becton Dickinson and Co (NYSE:BDX) raised the target price from $182.00 to $195.00. At the time, this suggested an upside of 0.12%.

Boasting a price of $181.55, Becton Dickinson and Co (NYSE:BDX) traded -1.13% lower on the day. The last close is up 7.59% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $175.35 and a 200-day moving average of $166.84. 1,175,868 shares of BDX traded, up from an avg. volume of 827,003

Performance Chart

Becton Dickinson and Co (NYSE:BDX)

Becton Dickinson and Co has a 52 week low of $128.87 and a 52 week high of $181.76 with a PE ratio of 34.26 BDX’s total market value is presently $0.

A total of 16 brokers have released a research note on Becton Dickinson and Co. Six equity analysts rating the company a strong buy, 5 brokers rating the stock a buy, 7 firms rating the stock a hold, 0 equity analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $173.94.

About Becton Dickinson and Co (NYSE:BDX)

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company operates through two business segments: BD Medical, which consists of Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, Pharmaceutical Systems and Respiratory Solutions business units, and BD Life Sciences, which consists of Preanalytical Systems, Diagnostic Systems and Biosciences business units. The Company's products include hypodermic needles and syringes; insulin syringes and pen needles; BD Hypak brand prefillable syringe systems; infusion therapy products, including Alaris infusion pumps; BD Vacutainer brand blood collection products, and flow cytometry instruments and reagents.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *